Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of $7.51 billion. The enterprise value is $8.06 billion.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 123.16 million shares outstanding. The number of shares has increased by 7.26% in one year.
| Current Share Class | 123.16M |
| Shares Outstanding | 123.16M |
| Shares Change (YoY) | +7.26% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 112.98% |
| Float | 122.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 85.27 |
| Forward PS | 52.74 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 91.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.53
| Current Ratio | 4.53 |
| Quick Ratio | 4.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -27.08% |
| Return on Invested Capital (ROIC) | -48.85% |
| Return on Capital Employed (ROCE) | -50.10% |
| Weighted Average Cost of Capital (WACC) | 6.83% |
| Revenue Per Employee | $130,816 |
| Profits Per Employee | -$1.17M |
| Employee Count | 673 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.16% in the last 52 weeks. The beta is 0.51, so Cytokinetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | +34.16% |
| 50-Day Moving Average | 63.67 |
| 200-Day Moving Average | 53.40 |
| Relative Strength Index (RSI) | 44.27 |
| Average Volume (20 Days) | 2,178,459 |
Short Selling Information
The latest short interest is 15.37 million, so 12.48% of the outstanding shares have been sold short.
| Short Interest | 15.37M |
| Short Previous Month | 14.78M |
| Short % of Shares Out | 12.48% |
| Short % of Float | 12.58% |
| Short Ratio (days to cover) | 8.39 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $88.04 million and -$784.96 million in losses. Loss per share was -$6.54.
| Revenue | 88.04M |
| Gross Profit | -327.99M |
| Operating Income | -612.26M |
| Pretax Income | -784.96M |
| Net Income | -784.96M |
| EBITDA | -602.13M |
| EBIT | -612.26M |
| Loss Per Share | -$6.54 |
Full Income StatementBalance Sheet
The company has $882.22 million in cash and $1.44 billion in debt, with a net cash position of -$556.62 million or -$4.52 per share.
| Cash & Cash Equivalents | 882.22M |
| Total Debt | 1.44B |
| Net Cash | -556.62M |
| Net Cash Per Share | -$4.52 |
| Equity (Book Value) | -659.63M |
| Book Value Per Share | -5.37 |
| Working Capital | 714.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$510.01 million and capital expenditures -$24.81 million, giving a free cash flow of -$534.82 million.
| Operating Cash Flow | -510.01M |
| Capital Expenditures | -24.81M |
| Depreciation & Amortization | 10.13M |
| Net Borrowing | 315.95M |
| Free Cash Flow | -534.82M |
| FCF Per Share | -$4.34 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -695.44% |
| Pretax Margin | -891.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.26% |
| Shareholder Yield | -7.26% |
| Earnings Yield | -10.46% |
| FCF Yield | -7.12% |
Analyst Forecast
The average price target for Cytokinetics is $88.50, which is 45.20% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $88.50 |
| Price Target Difference | 45.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 90.52% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
Cytokinetics has an Altman Z-Score of -2.59 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.59 |
| Piotroski F-Score | 3 |
